ARC Therapies

Executive Summary

ARC Therapies is a Tokyo-based preclinical biotech spin-out from Japan's National Cancer Center, founded in 2022. The company is developing novel cell and gene therapies for oncology, with initial focus on adult T-cell leukemia/lymphoma (ATLL) and gut microbiome-based cancer immunotherapies. Leveraging cutting-edge research in tumor immunology and translational expertise, ARC aims to address high unmet needs in hematologic and solid tumors. As an early-stage private company, it has not disclosed funding rounds or valuation. The preclinical stage means significant milestones lie ahead, including advancement toward IND-enabling studies and potential partnerships. The company's unique positioning within Japan's leading cancer research ecosystem provides a strong scientific foundation, but execution risks remain given the competitive cell therapy landscape.

Upcoming Catalysts (preview)

• H2 2026Preclinical data presentation at major oncology conference60% success
• H1 2027IND filing for lead ATLL cell therapy program30% success
• H2 2026Series A financing or strategic partnership50% success